Arcoma AB (ARCOMA.ST)
SEK 9.2
(5.02%)
SEK 9.2
(5.02%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 11.07 Million SEK | -78.05% |
| 2022 | 50.44 Million SEK | 21.13% |
| 2021 | 41.64 Million SEK | -7.96% |
| 2020 | 45.25 Million SEK | -12.81% |
| 2019 | 51.89 Million SEK | 10.95% |
| 2018 | 46.77 Million SEK | 27.1% |
| 2017 | 36.79 Million SEK | -15.44% |
| 2016 | 43.51 Million SEK | -13.0% |
| 2015 | 50.02 Million SEK | -9.66% |
| 2014 | 55.36 Million SEK | 30.73% |
| 2013 | 42.35 Million SEK | -17.07% |
| 2012 | 51.07 Million SEK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 3.36 Million SEK | -80.93% |
| 2024 Q3 | 13.2 Million SEK | 292.6% |
| 2024 Q1 | 17.63 Million SEK | 388.77% |
| 2023 Q3 | 13.95 Million SEK | -5.14% |
| 2023 Q1 | 12.23 Million SEK | -16.14% |
| 2023 FY | 11.07 Million SEK | -78.05% |
| 2023 Q4 | 3.6 Million SEK | -74.14% |
| 2023 Q2 | 14.7 Million SEK | 20.19% |
| 2022 Q1 | 11.48 Million SEK | 123.29% |
| 2022 FY | 50.44 Million SEK | 21.13% |
| 2022 Q4 | 14.59 Million SEK | 24.01% |
| 2022 Q2 | 12.94 Million SEK | 12.72% |
| 2022 Q3 | 11.76 Million SEK | -9.09% |
| 2021 Q1 | 14.3 Million SEK | 36.23% |
| 2021 Q4 | 5.14 Million SEK | -36.26% |
| 2021 Q2 | 14.15 Million SEK | -1.03% |
| 2021 Q3 | 8.06 Million SEK | -42.98% |
| 2021 FY | 41.64 Million SEK | -7.96% |
| 2020 Q2 | 10.77 Million SEK | -22.06% |
| 2020 Q1 | 13.81 Million SEK | -0.9% |
| 2020 Q3 | 10.16 Million SEK | -5.64% |
| 2020 Q4 | 10.49 Million SEK | 3.29% |
| 2020 FY | 45.25 Million SEK | -12.81% |
| 2019 Q2 | 14.02 Million SEK | 23.95% |
| 2019 Q4 | 13.94 Million SEK | 10.42% |
| 2019 Q3 | 12.62 Million SEK | -9.94% |
| 2019 Q1 | 11.31 Million SEK | -4.41% |
| 2019 FY | 51.89 Million SEK | 10.95% |
| 2018 Q4 | 11.83 Million SEK | 6.34% |
| 2018 FY | 46.77 Million SEK | 27.1% |
| 2018 Q3 | 11.12 Million SEK | -18.1% |
| 2018 Q2 | 13.58 Million SEK | 32.74% |
| 2018 Q1 | 10.23 Million SEK | -3.87% |
| 2017 Q1 | 10.61 Million SEK | -21.92% |
| 2017 FY | 36.79 Million SEK | -15.44% |
| 2017 Q4 | 10.64 Million SEK | 80.38% |
| 2017 Q3 | 5.9 Million SEK | -38.75% |
| 2017 Q2 | 9.63 Million SEK | -9.16% |
| 2016 FY | 43.51 Million SEK | -13.0% |
| 2016 Q4 | 13.58 Million SEK | 21.85% |
| 2016 Q3 | 11.15 Million SEK | 7.8% |
| 2016 Q2 | 10.34 Million SEK | 22.95% |
| 2016 Q1 | 8.41 Million SEK | -40.79% |
| 2015 Q1 | 16.83 Million SEK | 46.41% |
| 2015 Q2 | 9.17 Million SEK | -45.49% |
| 2015 Q3 | 9.79 Million SEK | 6.76% |
| 2015 FY | 50.02 Million SEK | -9.66% |
| 2015 Q4 | 14.2 Million SEK | 45.02% |
| 2014 Q1 | 15.23 Million SEK | 91.78% |
| 2014 Q2 | 16.98 Million SEK | 11.48% |
| 2014 Q3 | 11.36 Million SEK | -33.07% |
| 2014 Q4 | 11.49 Million SEK | 1.18% |
| 2014 FY | 55.36 Million SEK | 30.73% |
| 2013 Q3 | 8.83 Million SEK | 0.0% |
| 2013 FY | 42.35 Million SEK | -17.07% |
| 2013 Q4 | 7.94 Million SEK | -10.11% |
| 2012 FY | 51.07 Million SEK | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Acarix AB (publ) | 5.29 Million SEK | -109.005% |
| ADDvise Group AB (publ) | 300.6 Million SEK | 96.317% |
| ADDvise Group AB (publ) | 300.6 Million SEK | 96.317% |
| Bactiguard Holding AB (publ) | 139.98 Million SEK | 92.091% |
| BICO Group AB (publ) | 1.83 Billion SEK | 99.395% |
| Boule Diagnostics AB (publ) | 249.71 Million SEK | 95.567% |
| CellaVision AB (publ) | 463.04 Million SEK | 97.609% |
| Clinical Laserthermia Systems AB (publ) | 2.99 Million SEK | -269.403% |
| Chordate Medical Holding AB (publ) | -28.41 Million SEK | 138.963% |
| C-Rad AB (publ) | 66.01 Million SEK | 83.23% |
| Duearity AB (publ) | -4.17 Million SEK | 364.983% |
| Dignitana AB (publ) | 58.97 Million SEK | 81.226% |
| Episurf Medical AB (publ) | -41.8 Million SEK | 126.486% |
| Getinge AB (publ) | 13.43 Billion SEK | 99.918% |
| Scandinavian Real Heart AB (Publ) | -50.21 Million SEK | 122.046% |
| Iconovo AB (publ) | 17.57 Million SEK | 37.017% |
| Integrum AB (publ) | 690.56 Thousand SEK | -1503.187% |
| Luxbright AB (publ) | -2.79 Million SEK | 495.834% |
| Mentice AB (publ) | 236.38 Million SEK | 95.316% |
| OssDsign AB (publ) | 83.64 Million SEK | 86.764% |
| Paxman AB (publ) | 12.61 Million SEK | 12.26% |
| Promimic AB (publ) | 38.51 Million SEK | 71.255% |
| Qlife Holding AB (publ) | -50.75 Million SEK | 121.813% |
| SciBase Holding AB (publ) | 16.03 Million SEK | 30.966% |
| ScandiDos AB (publ) | 47.55 Million SEK | 76.72% |
| Sectra AB (publ) | 557.55 Million SEK | 98.014% |
| Sedana Medical AB (publ) | 108.98 Million SEK | 89.841% |
| Senzime AB (publ) | 8.33 Million SEK | -32.762% |
| SpectraCure AB (publ) | -9.22 Million SEK | 220.037% |
| Stille AB | 132.17 Million SEK | 91.624% |
| Vitrolife AB (publ) | 1.97 Billion SEK | 99.44% |
| Xvivo Perfusion AB (publ) | 416.91 Million SEK | 97.345% |